Allos Looks To Boost Lymphoma Drug Folotyn's Prospects With Mundipharma Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Currently the only approved drug for relapsed or refractory PTCL in the U.S., Folotyn may soon have competition from Celgene's Istodax.
You may also be interested in...
Investors Balk At AMAG-Allos Proposed Marriage
An all-stock merger worth up to $686 million would strengthen the companies' balance sheet, commercial presence, and cost structures, but Wall Street is concerned about logistics and execution.
Investors Balk At AMAG-Allos Proposed Marriage
An all-stock merger worth up to $686 million would strengthen the companies' balance sheet, commercial presence, and cost structures, but Wall Street is concerned about logistics and execution.
Celgene Pays $340 Million For Gloucester And Its New Drug
Celgene already sells several hematological cancer meds, so the deal shouldn't require new marketing infrastructure.